AUSTRALIAN based critical
medicines specialty pharmaceutical
company Phebra has announced a
new collaboration with US-based
pharmaceutical company Qrono
for the development of long-acting
injectable (LAI) drugs to treat
psychiatric disorders.
Phebra ceo Mal Eutick said
the company sees “tremendous
potential in applying Qrono’s
cutting-edge technology to develop
new medicines for the benefit of
people suffering mental illness”.
He said combining Qrono’s
expertise in long-acting formulation
development with Phebra’s
strong track record of successfully
commercialising sterile injectable
products would introduce a new
therapeutic option for psychiatric
patients.The above article was sent to subscribers in Pharmacy Daily's issue from 09 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 May 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.